share_log
Breakings ·  Jun 5 22:41
Royal Bank of Canada: Maintains a rating of Axsome Therapeutics (AXSM.US), adjusting from outperform to outperform rating, with a target price adjusted from $127.00 to $130.00.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment